Rapport Therapeutics, Inc. (RAPP) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders using its RAP (Receptor Associated Protein) technology platform. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator currently in Phase 2a trials for refractory focal epilepsy. The company is an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(24,063) | $(22,669) |
| Net Loss Per Share (Basic & Diluted) | $(0.68) | $(11.07) |
| Operating Expenses | $27,108 | $17,094 |
| Research & Development (R&D) | $19,572 | $12,504 |
| General & Administrative (G&A) | $7,536 | $4,590 |
| Interest Income | $3,045 | $1,815 |
| Cash, Cash Equivalents & Short-Term Investments | $285,382 | N/A |
| Accumulated Deficit | $(147,808) | N/A |
| Net Cash Used in Operating Activities | $(20,237) | $(17,615) |
Note: Q1 2024 per share data reflects a reverse stock split and preferred stock conversion that occurred in mid-2024, resulting in a significantly lower share count for that period.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $10.0 million (59%) to $27.1 million, driven primarily by increased R&D spending.
- R&D Growth: R&D expenses increased by $7.1 million (56%). This was largely due to a $4.1 million increase in RAP-219 program costs (clinical trial costs for focal epilepsy, DPNP, and bipolar mania) and a $2.8 million increase in personnel-related costs.
- G&A Growth: G&A expenses increased by $2.9 million (64%), primarily due to a $2.6 million increase in workforce expenses (salaries and stock-based compensation) and costs associated with operating as a public company.
- Other Income/Expense: The company reported $3.0 million in interest income, up from $1.8 million in the prior year, due to higher cash balances from the June 2024 IPO. Unlike Q1 2024, there was no expense related to the change in fair value of preferred stock tranche right liability, as that liability was settled in March 2024.
- Liquidity: As of March 31, 2025, the company held $285.4 million in cash, cash equivalents, and short-term investments, providing a runway through the end of 2026.
Guidance, Outlook, and Risks
- Clinical Progress: The company is conducting a Phase 2a proof-of-concept trial of RAP-219 in refractory focal epilepsy, with topline results expected in Q3 2025. A Phase 2a trial in bipolar mania is planned for initiation in Q3 2025.
- Regulatory Hold: The FDA placed a clinical hold on the Investigational New Drug (IND) application for RAP-219 in diabetic peripheral neuropathic pain (DPNP) in Q4 2024. The company is working to resolve this; the hold does not impact the ongoing focal epilepsy trial.
- Liquidity Outlook: Management expects existing cash resources to fund operations through the end of 2026. No specific revenue guidance is provided as the company has no commercial products.
- Key Risks:
- Dependence on the success of RAP-219 and the resolution of the FDA clinical hold for DPNP.
- Need for additional capital to fund future operations and clinical trials.
- Uncertainty regarding the translation of preclinical and early clinical data to registrational trials.
- Reliance on third-party manufacturers and CROs.
Investor Verification Checklist
- Verify the status and timeline for lifting the FDA clinical hold on the RAP-219 DPNP IND application.
- Monitor the enrollment progress and safety data of the ongoing Phase 2a trial in refractory focal epilepsy.
- Review the company's cash burn rate relative to the stated runway through the end of 2026.
- Assess the impact of the reverse stock split (completed May 2024) on historical per-share comparability.
- Confirm the terms and potential milestone obligations under the Janssen Pharmaceutical NV license agreement.